98 results on '"Wittmer C"'
Search Results
2. Electrospun silk fibers promote oriented axon regeneration of CNS neurons in vitro: OP-019
- Author
-
Claudepierre, T, Wittmer, C, Kaplan, D, Garlick, J, Egles, C, and Wiedemann, P
- Published
- 2011
3. Characteristic Pattern of Genetic Aberrations in Ovarian Granulosa Cell Tumors
- Author
-
Mayr, D, Kaltz-Wittmer, C, Arbogast, S, Amann, G, Aust, D E, and Diebold, J
- Published
- 2002
- Full Text
- View/download PDF
4. Critical raw materials and the circular economy
- Author
-
Mathieux, F., Ardente, F., Bobba, S., Nuss, P., Blengini, G., Alves, Dias, Blagoeva, P., Torres De Matos, Wittmer, C., Pavel, D., Hamor, C., Saveyn, T., Gawlik, H., Orveillon, B., Huygens, G., Garbarino, D., Tzimas, E., Bouraoui, E., and Solar, F.
- Subjects
products ,Critical aw materials ,science for policy ,circular economy ,Critical aw materials, science for policy, circular economy, products - Published
- 2017
5. Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction‐induced weight loss in rats
- Author
-
Trevaskis, J. L., primary, Wittmer, C., additional, Athanacio, J., additional, Griffin, P. S., additional, Parkes, D. G., additional, and Roth, J. D., additional
- Published
- 2016
- Full Text
- View/download PDF
6. Rapid Development of Non-Alcoholic Steatohepatitis in Psammomys obesus (Israeli Sand Rat)
- Author
-
Lobaccaro, J-MA, Spolding, B, Connor, T, Wittmer, C, Abreu, LLF, Kaspi, A, Ziemann, M, Kaur, G, Cooper, A, Morrison, S, Lee, S, Sinclair, A, Gibert, Y, Trevaskis, JL, Roth, JD, El-Osta, A, Standish, R, Walder, K, Lobaccaro, J-MA, Spolding, B, Connor, T, Wittmer, C, Abreu, LLF, Kaspi, A, Ziemann, M, Kaur, G, Cooper, A, Morrison, S, Lee, S, Sinclair, A, Gibert, Y, Trevaskis, JL, Roth, JD, El-Osta, A, Standish, R, and Walder, K
- Abstract
BACKGROUND AND AIMS: A major impediment to establishing new treatments for non-alcoholic steatohepatitis is the lack of suitable animal models that accurately mimic the biochemical and metabolic characteristics of the disease. The aim of this study was to explore a unique polygenic animal model of metabolic disease as a model of non-alcoholic steatohepatitis by determining the effects of 2% dietary cholesterol supplementation on metabolic and liver endpoints in Psammomys obesus (Israeli sand rat). METHODS: P. obesus were provided ad libitum access to either a standard rodent diet (20% kcal/fat) or a standard rodent diet supplemented with 2% cholesterol (w/w) for 4 weeks. Histological sections of liver from animals on both diets were examined for key features of non-alcoholic steatohepatitis. The expression levels of key genes involved in hepatic lipid metabolism were measured by real-time PCR. RESULTS: P. obesus fed a cholesterol-supplemented diet exhibited profound hepatomegaly and steatosis, and higher plasma transaminase levels. Histological analysis identified extensive steatosis, inflammation, hepatocyte injury and fibrosis. Hepatic gene expression profiling revealed decreased expression of genes involved in delivery and uptake of lipids, and fatty acid and triglyceride synthesis, and increased expression of genes involved in very low density lipoprotein cholesterol synthesis, triglyceride and cholesterol export. CONCLUSIONS: P. obesus rapidly develop non-alcoholic steatohepatitis when fed a cholesterol-supplemented diet that appears to be histologically and mechanistically similar to patients.
- Published
- 2014
7. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents
- Author
-
Trevaskis, J. L., primary, Sun, C., additional, Athanacio, J., additional, D'Souza, L., additional, Samant, M., additional, Tatarkiewicz, K., additional, Griffin, P. S., additional, Wittmer, C., additional, Wang, Y., additional, Teng, C.-H., additional, Forood, B., additional, Parkes, D. G., additional, and Roth, J. D., additional
- Published
- 2014
- Full Text
- View/download PDF
8. 733 A tertiary Gleason pattern exerts a different prognostic effect after radical prostatectomy in patients with different Gleason scores
- Author
-
Adam, M., primary, Amir, H., additional, Michl, U., additional, Fisch, M., additional, Wittmer, C., additional, Steurer, S., additional, Minner, S., additional, Heinzer, H., additional, Huland, H., additional, Sauter, G., additional, Schlomm, T., additional, and Isbarn, H., additional
- Published
- 2014
- Full Text
- View/download PDF
9. V37 A feasible and time-efficient adaption of the NeuroSAFE intraoperative frozen section technique to DaVinci-robot-assisted radical prostatectomy
- Author
-
Haese, A., primary, Schlomm, T., additional, Boehm, K., additional, Schiffmann, J., additional, Tennstedt, P., additional, Graefen, M., additional, Huland, H., additional, Steuber, T., additional, Sauter, G., additional, Wittmer, C., additional, and Beyer, B., additional
- Published
- 2014
- Full Text
- View/download PDF
10. Fibronectin terminated multilayer films: Protein adsorption and cell attachment studies
- Author
-
WITTMER, C, primary, PHELPS, J, additional, SALTZMAN, W, additional, and VANTASSEL, P, additional
- Published
- 2007
- Full Text
- View/download PDF
11. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients
- Author
-
Goekkurt, E, primary, Hoehn, S, additional, Wolschke, C, additional, Wittmer, C, additional, Stueber, C, additional, Hossfeld, D K, additional, and Stoehlmacher, J, additional
- Published
- 2005
- Full Text
- View/download PDF
12. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients.
- Author
-
Goekkurt, E., Hoehn, S., Wolschke, C., Wittmer, C., Stueber, C., Hossfeld, D. K., and Stoehlmacher, J.
- Subjects
GLUTATHIONE transferase ,TRANSFERASES ,ENZYMES ,GENETIC polymorphisms ,STOMACH cancer ,CANCER patients - Abstract
To evaluate the predictive value of a panel of gene polymorphisms involved in metabolism of 5-FU and cisplatin on clinical outcome in advanced gastric cancer patients. A total of 52 patients were enrolled in this study. DNA was extracted from paraffin-embedded tumour specimen. Genotypes were determined using PCR-RFLP. Median survival time was 6.0 months (95% CI 3.9;8.1). Overall response rate was 26%. Patients possessing the glutathione S-transferase P1-105 Valine/Valine (GSTP1-105VV) genotype showed a response rate of 67% compared to 21% in patients harbouring at least one GSTP1-105 Isoleucine (GSTP1-105I) allele (P=0.038). GSTP1-105VV patients demonstrated a significant superior median survival time of 15.0 months (95% CI 7.8;22.0) compared to 6.0 months (95% CI 5.1;7.0) in patients with at least one GSTP1-105I allele (P=0.037). Patients possessing a favourable thymidylate synthase (TS) genotype (2R/2R, 2R/3RC, 3RC/3RC) experienced a superior survival time of 10.2 months (95% CI 5.1;15.3) compared to 6.0 months (95% CI 5.0;7.0) in patients with unfavourable TS genotypes (P=0.099). Patients harbouring the GSTP1-105II genotype and one of the unfavourable TS genotypes showed an inferior median survival time of 6.0 months (95% CI 3.9;8.1) compared to 11 months (95% CI 6,23;15,77) in patients with either GSTP1-105VV or a favourable TS genotype (P=0.044). Testing for TS and GSTP1 polymorphisms may allow identification of gastric cancer patients who will benefit from 5-FU/cisplatin chemotherapy, sparing others the side effects of this chemotherapy.British Journal of Cancer (2006) 94, 281–286. doi:10.1038/sj.bjc.6602891 www.bjcancer.com Published online 29 November 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
13. Self-reported asthma and allergies in top athletes compared to the general population - results of the German part of the GA2LEN-Olympic study 2008
- Author
-
Thomas Silke, Wolfarth Bernd, Wittmer Caroline, Nowak Dennis, and Radon Katja
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Prevalence of asthma and allergies in top athletes is high. However, most previous studies did not include a general population comparison group. We aimed to compare the prevalence of asthma, allergies and medical treatment in different groups of German top athletes to the general population. Methods Prior to the 2008 Summer Olympic Games, 291 German candidates for participation (65%) completed a questionnaire on respiratory and allergic symptoms. Results were compared to those of a general population study in Germany (n = 2425, response 68%). Furthermore, associations between types of sports and the self-reported outcomes were calculated. All models were adjusted for age, sex, level of education and smoking. Results Athletes reported significantly more doctors' diagnosed asthma (17% vs. 7%), more current use of asthma medication (10% vs. 4%) and allergic rhinitis (25% vs. 17%) compared to the general population. After adjustment, top athletes only had an increased Odds Ratio for doctor's diagnosed asthma (OR: 1.6; 95% CI 1.1-2.5). Compared to the general population, athletes in endurance sports had an increased OR for doctor's diagnosed asthma (2.4; 1.5-3.8) and current use of asthma medication (1.8; 1.0-3.4). In this group, current wheeze was increased when use of asthma medication was taken into account (1.8; 1.1-2.8). For other groups of athletes, no significantly increased ORs were observed. Conclusions Compared to the general population, an increased risk of asthma diagnosis and treatment was shown for athletes involved in endurance sports. This might be due to a better medical surveillance and treatment of these athletes.
- Published
- 2010
- Full Text
- View/download PDF
14. NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease.
- Author
-
Khan A, Johnson R, Wittmer C, Maile M, Tatsukawa K, Wong JL, Gill MB, Stocking EM, Natala SR, Paulino AD, Bowden-Verhoek JK, Wrasidlo W, Masliah E, Bonhaus DW, and Price DL
- Subjects
- Animals, Brain pathology, Humans, Mice, Mice, Transgenic, Synucleinopathies pathology, Brain drug effects, Motor Activity drug effects, Neuroprotective Agents pharmacology, Parkinsonian Disorders pathology
- Abstract
NPT520-34 is a clinical stage, small molecule being developed for the treatment of Parkinson's disease and other neurodegenerative disorders. The therapeutic potential of NPT520-34 was first suggested by findings from cell-based assays of alpha-synuclein clearance. As reported here, NPT520-34 was subsequently evaluated for therapeutically relevant actions in a transgenic animal model of Parkinson's disease that overexpresses human alpha-synuclein and in an acute lipopolysaccharide-challenge model using wild-type mice. Daily administration of NPT520-34 to mThy1-alpha-synuclein (Line 61) transgenic mice for 1 or 3 months resulted in reduced alpha-synuclein pathology, reduced expression of markers of neuroinflammation, and improvements in multiple indices of motor function. In a lipopolysaccharide-challenge model using wild-type mice, a single dose of NPT520-34 reduced lipopolysaccharide-evoked increases in the expression of several pro-inflammatory cytokines in plasma. These findings demonstrate the beneficial effects of NPT520-34 on both inflammation and protein-pathology end points, with consequent improvements in motor function in an animal model of Parkinson's disease. These findings further indicate that NPT520-34 may have two complementary actions: (i) to increase the clearance of neurotoxic protein aggregates; and (ii) to directly attenuate inflammation. NPT520-34 treatment may thereby address two of the predominate underlying pathophysiological aspects of neurodegenerative disorders such as Parkinson's disease., (© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
15. Pattern of placental alkaline phosphatase (PLAP) expression in human tumors: a tissue microarray study on 12,381 tumors.
- Author
-
Reiswich V, Gorbokon N, Luebke AM, Burandt E, Menz A, Kluth M, Hube-Magg C, Wittmer C, Weidemann S, Fraune C, Möller K, Lebok P, Sauter G, Simon R, Uhlig R, Wilczak W, Jacobsen F, Minner S, Krech R, Bernreuther C, Marx A, Steurer S, Clauditz T, and Krech T
- Subjects
- Blood Vessels enzymology, Blood Vessels pathology, Female, GPI-Linked Proteins analysis, Germany, Humans, Lymphatic Metastasis, Male, Neoplasm Invasiveness, Neoplasm Staging, Neoplasms pathology, Predictive Value of Tests, Alkaline Phosphatase analysis, Biomarkers, Tumor analysis, Immunohistochemistry, Isoenzymes analysis, Neoplasms enzymology, Tissue Array Analysis
- Abstract
Placental alkaline phosphatase (PLAP) is commonly expressed at high levels in testicular germ cell tumors. PLAP immunohistochemistry (IHC) is thus often used to confirm this diagnosis, especially in cases of putative metastasis. However, other tumors can also express PLAP. To comprehensively determine PLAP expression in normal and tumor tissue, a tissue microarray containing 16,166 samples from 131 different tumor types and subtypes as well as 608 samples from 76 different normal tissue types was analyzed by IHC. Moderate to strong PLAP positivity was found in 27 (21%) of 131 different tumor types including seminoma (96%), embryonal carcinoma (85%), and yolk sac tumors of the testis (56%); endometrioid carcinoma of the endometrium (28%) and the ovary (20%); gastric adenocarcinoma (22%); serous carcinoma (not otherwise specified) of the ovary (17%) and the uterus (11%); adenocarcinoma of the ampulla of Vater (15%); carcinosarcoma of the ovary (11%) and the uterus (8%); esophageal adenocarcinoma (10%); invasive urothelial carcinoma (4%); cholangiocarcinoma (2%); and adenocarcinoma of the lung (1%). Low-level PLAP immunostaining, often involving only a small fraction of tumor cells, was seen in 21 additional tumor entities. The clinical significance of PLAP expression may vary between tumor types as high PLAP expression was linked to advanced pathological tumor stage (p = 0.0086), nodal metastasis (p = 0.0085), and lymphatic (p = 0.0007) and blood vessel invasion (p = 0.0222) in colorectal cancer, but to low pathological tumor stage in endometrial cancer (p = 0.0043). In conclusion, our data identify several tumor entities that can show PLAP expression at comparable levels to testicular germ cell tumors. These tumor entities need to be considered in cases of PLAP-positive metastasis. Low-level PLAP expression can be found in various other tumor entities and should generally not be viewed as a strong argument for germ cell neoplasia., (© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
16. Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer.
- Author
-
Höflmayer D, Fraune C, Hube-Magg C, Simon R, Schroeder C, Büscheck F, Möller K, Dum D, Weidemann S, Wittmer C, Schlomm T, Huland H, Heinzer H, Graefen M, Haese A, Sauter G, Burandt E, Clauditz TS, Steurer S, Minner S, Wilczak W, and Polonski A
- Subjects
- Aged, Disease-Free Survival, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Carrier Proteins biosynthesis, Carrier Proteins genetics, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Genomic Instability, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, Prostatic Neoplasms enzymology, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality, Ubiquitin-Protein Ligases biosynthesis, Ubiquitin-Protein Ligases genetics
- Abstract
Tripartite motif containing 24 (TRIM24) is a multifunctional protein involved in p53 degradation, chromatin binding, and transcriptional modulation of nuclear receptors. Emerging research has revealed that upregulation of TRIM24 in numerous tumor types is linked to poor prognosis, attributing an important role to TRIM24 in tumor biology. In order to better understand the role of TRIM24 in prostate cancer, we analyzed its immunohistochemical expression on a tissue microarray containing >17,000 prostate cancer specimens. TRIM24 immunostaining was detectable in 61% of 15,321 interpretable cancers, including low expression in 46% and high expression in 15% of cases. TRIM24 upregulation was associated with high Gleason grade, advanced pathologic tumor stage, lymph node metastasis, higher preoperative prostate-specific antigen level, increased cell proliferation as well as increased genomic instability, and predicted prognosis independent of clinicopathologic parameters available at the time of the initial biopsy (all P<0.0001). TRIM24 upregulation provides additional prognostic information in prostate cancer, particularly in patients with low Gleason grade tumors who may be eligible for active surveillance strategies, suggesting promising potential for TRIM24 in the routine diagnostic work-up of these patients., Competing Interests: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
17. A non-diploid DNA status is linked to poor prognosis in renal cell cancer.
- Author
-
Büscheck F, Fraune C, Kluth M, Lennartz M, Simon R, Hube-Magg C, Morlock C, Barbieri S, Wahl C, Eichelberg C, Möller-Koop C, Höflmayer D, Wittmer C, Wilczak W, Sauter G, Fisch M, Eichenauer T, and Rink M
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Renal Cell mortality, Humans, Kidney Neoplasms mortality, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Carcinoma, Renal Cell chemistry, Carcinoma, Renal Cell genetics, DNA, Neoplasm analysis, DNA, Neoplasm genetics, Kidney Neoplasms chemistry, Kidney Neoplasms genetics, Ploidies
- Abstract
Purpose: DNA ploidy measurement has earlier been suggested as a potentially powerful prognostic tool in many cancer types, but the role in renal tumors is still unclear., Methods: To clarify its prognostic impact, we analyzed the DNA content of 1320 kidney tumors, including clear cell, papillary and chromophobe renal cell carcinoma (RCC) as well as renal oncocytoma and compared these data with clinico-pathological parameters and patient prognosis., Results: A non-diploid DNA content was seen in 37% of 1276 analyzable renal tumors with a striking predominance in chromophobe carcinoma (74.3% of 70 cases). In clear cell carcinoma, a non-diploid DNA content was significantly linked to high-grade (ISUP, Fuhrman, Thoenes; p < 0.0001 each), advanced tumor stage (p = 0.0011), distant metastasis (p < 0.0001), shortened overall survival (p = 0.0010), and earlier recurrence (p < 0.0001). In papillary carcinoma, an aberrant DNA content was significantly linked to high Fuhrman grade (p = 0.0063), distant metastasis (p = 0.0138), shortened overall survival (p = 0.0010), and earlier recurrence (p = 0.0003)., Conclusion: In summary, the results of our study identify a non-diploid DNA content as a predictor of an unfavorable prognosis in clear cell and papillary carcinoma.
- Published
- 2021
- Full Text
- View/download PDF
18. Y-chromosome loss is frequent in male renal tumors.
- Author
-
Büscheck F, Fraune C, Garmestani S, Simon R, Kluth M, Hube-Magg C, Ketterer K, Eichelberg C, Höflmayer D, Jacobsen F, Wittmer C, Wilczak W, Sauter G, Fisch M, Eichenauer T, and Rink M
- Abstract
Background: Loss of the Y-chromosome is a common event in different tumor types but its prevalence and clinical relevance in renal cell tumors is still not understood., Methods: It was the aim of this study to estimate the frequency and clinical relevance of Y-loss in kidney neoplasms. A cohort of 1,252 male renal tumors was analyzed in a tissue microarray format by fluorescence in-situ hybridization (FISH)., Results: Y-loss was found in 47% of tumors. The frequency of this alteration varied markedly between kidney tumor subtypes. Y-loss was most prevalent in papillary renal cell carcinoma (RCC) (77%) followed by chromophobe RCC (60%), oncocytoma (51%), clear cell RCC (39%) and clear cell (tubulo)papillary RCC (19%). Y-loss was linked to higher patient age and smaller tumor size at diagnosis. Mean age (95% CI) was 65 (64-66) years in patients with Y-loss in their tumor compared to 60 (58-61) years in patients without Y-loss (P<0.0001). Significant correlations between Y-loss and tumor phenotype were found only for papillary carcinomas (P=0.002), especially for type 1 (P=0.03)., Conclusions: Y-loss is present in different histologic subtypes of renal neoplasm. The highest frequency is in papillary RCC, where it may represent a potentially relevant prognostic biomarker suggesting favorable disease outcome., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3061). The authors have no conflicts of interest to declare., (2021 Annals of Translational Medicine. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
19. Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.
- Author
-
Freytag M, Kluth M, Bady E, Hube-Magg C, Makrypidi-Fraune G, Heinzer H, Höflmayer D, Weidemann S, Uhlig R, Huland H, Graefen M, Bernreuther C, Wittmer C, Tsourlakis MC, Minner S, Dum D, Hinsch A, Luebke AM, Simon R, Sauter G, Schlomm T, and Möller K
- Subjects
- Aged, Biomarkers, Tumor genetics, Case-Control Studies, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms metabolism, Prostatic Neoplasms surgery, RNA-Binding Proteins genetics, Survival Rate, Biomarkers, Tumor metabolism, Prostatectomy methods, Prostatic Neoplasms pathology, RNA-Binding Proteins metabolism
- Abstract
Background: Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimate the impact of ESRP1 and ESRP2 alterations on prostate cancer patient prognosis., Methods: A tissue microarray made from 17,747 individual cancer samples with comprehensive, pathological, clinical and molecular data was analyzed by immunohistochemistry for ESRP1 and ESRP2., Results: Nuclear staining for ESRP1 was seen in 38.6% (36.0% low, 2.6% high) of 12,140 interpretable cancers and in 41.9% (36.4% low, 5.3% high) of 12,962 interpretable cancers for ESRP2. Nuclear protein expression was linked to advanced tumor stage, high Gleason score, presence of lymph node metastasis, early biochemical recurrence, and ERG-positive cancers (p < 0.0001 each). Expression of ESRPs was significantly linked to 11 (ESRP1)/9 (ESRP2) of 11 analyzed deletions in all cancers and to 8 (ESRP1)/9 (ESRP2) of 11 deletions in ERG-negative cancers portending a link to genomic instability. Combined ESRPs expression analysis suggested an additive effect and showed the worst prognosis for cancers with high ESRP1 and ESRP2 expression. Multivariate analyses revealed that the prognostic impact of ESRP1, ESRP2 and combined ESRP1/ESRP2 expression was independent of all established pre- and postoperative prognostic features., Conclusions: Our data show a striking link between nuclear ESRP expression and adverse features in prostate cancer and identifies expression of ESRP1 and/or ESRP2 as independent prognostic markers with a potential for routine application.
- Published
- 2020
- Full Text
- View/download PDF
20. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
- Author
-
Bernreuther C, Daghigh F, Möller K, Hube-Magg C, Lennartz M, Lutz F, Rico SD, Fraune C, Dum D, Luebke AM, Eichenauer T, Möller-Koop C, Schlomm T, Wittmer C, Huland H, Heinzer H, Graefen M, Haese A, Burandt E, Tsourlakis MC, Clauditz TS, Höflmayer D, Izbicki JR, Simon R, Sauter G, Minner S, Steurer S, and Meiners J
- Subjects
- Aged, Biomarkers, Tumor metabolism, Case-Control Studies, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Prostatic Neoplasms surgery, Proto-Oncogene Proteins metabolism, Survival Rate, Tissue Array Analysis, Transcriptional Regulator ERG genetics, Biomarkers, Tumor genetics, Oncogene Proteins, Fusion genetics, Prostatic Neoplasms pathology, Proto-Oncogene Proteins genetics, Serine Endopeptidases genetics
- Abstract
Secreted frizzled-related protein 4 (SFRP4) controls WNT signaling and is thought to play a role for tumor aggressiveness. Here, we analyzed a tissue microarray containing 11,152 prostate cancers with pathological, clinical and molecular data by immunohistochemistry. SFRP4 expression was higher in cancer than in non-neoplastic acinar cells. SFRP4 staining was seen in 64.9% of tumors and classified as weak in 33.2%, moderate in 23.9% and strong in 7.8% of cancers. SFRP4 overexpression was linked to advanced tumor stage, high classical/quantitative Gleason grade (p < 0.0001 each), lymph node metastasis (p = 0.0002), and a positive surgical margin (p = 0.0017). SFRP4 positivity was markedly more frequent in ERG positive (77.4%) than in ERG negative cancers (57.4% p < 0.0001). Subset analyses in 2725 cancers with and 3592 cancers without TMPRSS2:ERG fusion revealed that associations with tumor phenotype and patient outcome were largely driven by the subset of ERG negative tumors. In a multivariate analysis including various postoperative and prognostic clinico-pathological features, SFRP4 protein expression emerged as an independent prognostic parameter in ERG negative cancers. SFRP4 immunostaining was significantly linked with 10 of 11 previously analyzed chromosomal deletions (p < 0.05 each). In conclusion, high SFRP4 immunostaining is associated with poor prognosis and genomic instability in ERG negative prostate cancers.
- Published
- 2020
- Full Text
- View/download PDF
21. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
- Author
-
Luebke AM, Ricken W, Kluth M, Hube-Magg C, Schroeder C, Büscheck F, Möller K, Dum D, Höflmayer D, Weidemann S, Fraune C, Hinsch A, Wittmer C, Schlomm T, Huland H, Heinzer H, Graefen M, Haese A, Minner S, Simon R, Sauter G, Wilczak W, and Meiners J
- Subjects
- Gene Expression Regulation, Neoplastic, Humans, Lymphatic Metastasis, Male, Neoplasm Grading, Prognosis, Prostate-Specific Antigen metabolism, Prostatectomy, Prostatic Neoplasms metabolism, Sequence Deletion, Tissue Array Analysis, Treatment Outcome, Antigens, CD metabolism, Cell Adhesion Molecules metabolism, Down-Regulation, Oncogene Proteins, Fusion metabolism, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery
- Abstract
Altered expression of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been linked to adverse tumor features in various cancer types. To better understand the role of CEACAM1 in prostate cancer, we analyzed a tissue microarray containing tumor spots from 17,747 prostate cancer patients by means of immunohistochemistry. Normal prostate glands showed intense membranous CEACAM1 positivity. Immunostaining was interpretable in 13,625 cancers and was considered high in 28%, low in 43% and absent in 29% of tumors. Low and lost CEACAM1 expression was strongly linked to adverse tumor features including high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, positive surgical margin, a high number of genomic deletions and early biochemical recurrence (p < 0.0001 each). Subset analysis of molecularly defined cancer subsets revealed that these associations were strongest in V-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion-positive cancers and that CEACAM1 loss was prognostic even in tumors harboring genomic deletions of the phosphatase and tensin homolog tumor suppressor (p < 0.0001). Multivariate analysis suggested that CEACAM1 analysis can provide independent prognostic information beyond established prognosis parameters at the stage of the initial biopsy when therapy decisions must be taken. In conclusion, loss of CEACAM1 expression predicts poor prognosis in prostate cancer and might provide clinically useful prognostic information particularly in cancers harboring the TMPRSS2:ERG fusion., (© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2020
- Full Text
- View/download PDF
22. 8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival.
- Author
-
Eichenauer T, Bannenberg DC, Kluth M, Wittmer C, Büscheck F, Möller K, Dum D, Fraune C, Hube-Magg C, Möller-Koop C, Dahlem R, Fisch M, Rink M, Riechardt S, Tsourlakis MC, Bernreuther C, Minner S, Simon R, Sauter G, Wilczak W, and Clauditz TS
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Renal Cell mortality, Chromosome Deletion, Chromosomes, Human, Pair 8 genetics, Female, Humans, Kidney Neoplasms mortality, Male, Middle Aged, Survival Analysis, Carcinoma, Renal Cell genetics, In Situ Hybridization, Fluorescence methods, Kidney Neoplasms genetics
- Abstract
Background and Methods: 8p deletions are common in renal cell carcinoma. To study their prognostic impact and association with kidney cancer phenotype, a tissue microarray with 1,809 cancers was analyzed by fluorescence in situ hybridization for 8p21 copy numbers., Results: One thousand four hundred and seventy four interpretable tumors showed substantial differences between renal cancer subtypes. That 8p deletion was only seen in 1 (0.5%) of 216 papillary carcinomas underscores the biologic uniqueness of papillary kidney cancer, which is also defined by a highly distinct morphology. 8p deletions were found in 13.2% of 976 clear cell carcinomas, 7.8% of 77 chromophobe carcinomas, 0.8% of 119 oncocytomas, but also in several rare tumor entities including 1 of 4 collecting duct cancers, 1 of 3 multilocular cystic clear cell renal cell neoplasm of low malignancy, 2 of 10 Xp11.2 translocation cancers, 3 of 18 not otherwise specified carcinomas, and 1 analyzed medullary carcinoma. In clear cell carcinomas, 8p deletions were significantly associated with higher International Society of Urologic Pathologists (ISUP) grading (P = 0.0014), Fuhrman (P = 0.0003) and Thoenes grade (P = 0.0033), advanced tumor stage (P = 0.0002), large tumor diameter (P = 0.0019), distant metastases (P = 0.0183), overall survival (P = 0.0394), and recurrence free survival (P < 0.0001). In multivariate analysis, the prognostic role of 8p deletions was not independent of established clinic-pathological parameters. In conclusion, 8p deletions are strongly linked to tumor aggressiveness in clear cell kidney cancer., Conclusions: Because 8p deletions are easy to measure by fluorescence in situ hybridization, 8p deletion assessment, most likely in combination with other parameters, may have a role in future prognosis assessment in clear cell kidney cancer., (Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
23. Expression of the immune checkpoint receptor TIGIT in seminoma.
- Author
-
Hinsch A, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, and Wilczak W
- Abstract
A characteristic feature of testicular seminoma is the abundance of immune cells in the tumor microenvironment, raising the possibility that immune checkpoint inhibitors may serve as a therapeutic option in these types of tumors. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor in analogy to PD-1, and drugs targeting TIGIT are currently being investigated in clinical trials. Little is known about the expression of these proteins in testicular seminomas. Therefore the present study performed immunohistochemical analysis to determine the relative abundance of TIGIT and PD-1 in relation to the total CD3
+ immune cell infiltration in a tissue microarray (TMA) constructed from 78 seminoma patients. The fraction of TIGIT+ and PD-1+ lymphocytes was highly variable in individual cancers and ranged from 2.3 to 69.4% (mean: 32.2±14.7%) for TIGIT and from 0.8 to 56.5% (mean: 21.6±13.2%) for PD-1. The same high degree of variability was also identified for the ratio of PD-1 to TIGIT positive cells, which varied from a dominance of TIGIT (PD-1: TIGIT ratio=0.02) in 74% of patients, to a predominance of PD-1 (PD-1: TIGIT ratio=12.5) in 23% of patients. In summary, the immune checkpoint receptors TIGIT and PD-1 are abundantly expressed in human seminomas. Once available, anti-TIGIT antibodies, possibly in combination with anti-PD-1 drugs, may be a reasonable therapeutic strategy for this type of cancer.- Published
- 2019
- Full Text
- View/download PDF
24. 5q21 deletion is often heterogeneous in prostate cancer.
- Author
-
Kluth M, Al Kilani Z, Özden C, Hussein K, Frogh S, Möller-Koop C, Burandt E, Steurer S, Büscheck F, Jacobsen F, Luebke AM, Minner S, Tsourlakis MC, Hoeflmayer D, Wittmer C, Schlomm T, Sauter G, Simon R, and Wilczak W
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Chromosomes, Human, Pair 6, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Chromosome Deletion, Chromosomes, Human, Pair 5, Genetic Heterogeneity, Prostatic Neoplasms genetics
- Abstract
Cancer heterogeneity represents a challenge for the analysis of prognostic molecular markers but can be used to study the evolution of molecular events in tumors. To assess the degree of heterogeneity of 5q21 deletions and their relationship with TMPRSS2:ERG status and 6q15 deletions in prostate cancer, a heterogeneity tissue microarray including 10 tissue spots from 10 different areas of 317 cancers was analyzed by fluorescence in situ hybridization for 5q21 deletion. Data on 6q and ERG were available from earlier studies. Deletions of 5q21 were found in 23% of 265 interpretable cancers and showed marked intratumoral heterogeneity. In the subset of 246 cancers with at least 3 interpretable spots, 23% had a 5q21 deletion. Heterogeneous 5q21 deletions were found in 71% and homogeneous in 29% of these cancers. The likelihood of 5q21 deletion was twice as high in ERG-negative (28%) than in ERG-positive cancers (16%, P = .024). In all 21 cases harboring both alterations, the tumor area containing a 5q21 deletion was smaller or equally large than the ERG-positive area but never larger. Deletions of 5q and 6q were significantly linked. However, the analysis of 32 tumors harboring both deletions did not suggest a specific order of appearance of these deletions. The 5q21 deletion preceded 6q15 in 10 tumors and 6q15 preceded 5q21 in 14 tumors. In summary, our study identifies 5q21 deletion as a highly heterogeneous aberration in prostate cancer that usually occurs late during cancer progression. This is a severe limitation for using 5q21 testing as a prognostic tool., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
25. Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.
- Author
-
Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li W, Wellge B, Debatin NF, Höflmayer D, Izbicki JR, Büscheck F, Luebke AM, Wittmer C, Jacobsen F, Lutz F, Burandt E, Steurer S, Sauter G, Tsourlakis MC, Wilczak W, Hinsch A, and Minner S
- Subjects
- B7-H1 Antigen genetics, Carcinoma, Small Cell pathology, Humans, Phenotype, Urinary Bladder Neoplasms pathology, B7-H1 Antigen metabolism, Carcinoma, Small Cell immunology, Lymphocytes, Tumor-Infiltrating immunology, Urinary Bladder Neoplasms immunology
- Abstract
Small-cell cancer of the urinary bladder is a rare but highly aggressive disease. It is currently unclear whether immune checkpoint therapies that have been approved for urothelial carcinomas will also be efficient in small-cell carcinomas. In this study, we analyzed potential predictors of response including PD-L1 expression and the quantity and location of tumor-infiltrating lymphocytes (TILs) in 12 small-cell and 69 "classical" urothelial cancers by immunohistochemistry. The analysis revealed that small-cell carcinomas were characterized by the virtual absence of PD-L1 expression and an "immune-excluded" phenotype with only a few TILs in the center of the tumor (CT). In small-cell carcinomas, the average immune cell density in the CT (CD3: 159 ± 206, CD8: 87 ± 169 cells/mm
2 ) was more than 3 times lower than that in the urothelial carcinomas (CD3: 625 ± 800, p < 0.001; CD8: 362 ± 626 cells/mm2 , p = 0.004) while there was no significant difference in the immune cell density at the invasive margin (IM) (small-cell carcinomas CD3: 899 ± 733, CD8: 404 ± 433 cells/mm2 ; urothelial carcinomas CD3: 1167 ± 1206, p = 0.31; CD8: 582 ± 864 cells/mm2 , p = 0.27). Positive PD-L1 staining was found in 39% of urothelial cancers, but in only 8% of small-cell bladder cancer cases ( p = 0.04). Concordant with these data, a sharp decrease of PD-L1 positivity from >80% to 0% positive cells and of TILS in the CT from 466-1063 CD3-positive cells/mm2 to 50-109 CD3-positive cells/mm2 was observed in two cancers with clear-cut progression from "classical" urothelial to small-cell carcinoma. In conclusion, these data demonstrate that small-cell bladder cancer commonly exhibits an immune-excluded phenotype.- Published
- 2019
- Full Text
- View/download PDF
26. Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.
- Author
-
Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt EC, Steurer S, Wilczak W, and Hinsch A
- Subjects
- Humans, Immune System Diseases metabolism, Neoplasms metabolism, Palatine Tonsil metabolism, Receptors, Immunologic metabolism, Immune System Diseases genetics, Lymph Nodes metabolism, Neoplasms genetics, Receptors, Immunologic genetics
- Abstract
TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel immune therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and various inflamed tissues, colorectal and lung cancers, as well as >1700 tumour samples from 86 different tumour entities for TIGIT and/or PD-1 by bright field and/or multiplex fluorescence immunohistochemistry. TIGIT was detected in CD8
+ cytotoxic T cells, CD4+ T helper cells, FOXP3+ regulatory T cells, and NK cells, but not in CD11c+ dendritic cells, CD68+ macrophages, and CD20+ B lymphocytes. TIGIT expression paralleled that of PD-1. More than 70% of TIGIT+ cells were PD-1+ , and more than 90% of the PD-1+ cells were TIGIT+ . Expression varied between different tissue compartments. TIGIT expression in tonsil gradually increased from the interfollicular area over the marginal/mantle zone to the germinal centre in all T cell subtypes. In inflammatory diseases, the strongest expression of TIGIT/PD-1 was found in Hashimoto thyroiditis. TIGIT+ lymphocytes were seen in all 86 different tumour entities with considerable high variability of TIGIT positivity within and between different cancer entities. Particularly, high densities of TIGIT+ lymphocytes were, for example, seen in squamous cell cancers of various origins. In summary, the variable expression levels of TIGIT and PD-1 in cell types and tissue compartments illustrate the high complexity of immune microenvironments. The high frequency of TIGIT (and PD-1) expressing lymphocytes in cancers highlights considerable opportunities for cotargeting with checkpoint inhibitors.- Published
- 2019
- Full Text
- View/download PDF
27. Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.
- Author
-
Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Pott L, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W, and Hinsch A
- Subjects
- Genes, cdc, Hodgkin Disease pathology, Humans, Receptors, Immunologic genetics, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes pathology, Tumor Microenvironment physiology, Gene Expression Regulation, Neoplastic, Hodgkin Disease immunology, Hodgkin Disease metabolism, Receptors, Immunologic biosynthesis, Receptors, Immunologic immunology
- Abstract
Hodgkin's lymphoma (HL) is characterized by a high background of inflammatory cells which play an important role for the pathogenesis of the disease. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor and a putative target for novel immunotherapies. To study patterns of TIGIT expression in the T cell background surrounding malignant cells including Hodgkin cells, Reed-Sternberg cells and histiocytic cells, a microenvironment (ME) tissue microarray (TMA) was constructed from tissue punches measuring 2 mm in diameter obtained from formalin-fixed tissue samples of Hodgkin's lymphoma lymph nodes (n = 40) and normal human tonsil (n = 2). The ME-TMA was stained by brightfield and fluorescence multiplex immunohistochemistry (IHC) to evaluate expression levels of TIGIT and PD-1 as well as standard lymphocyte markers (CD3, CD8, CD4, FOXP3) in the lymphocytic background. All analyzed cases of HL contained 9-99% (median: 86%) of TIGIT
+ lymphoid cells. In general, TIGIT localized to the same cells as PD-1. Strikingly, expression levels of TIGIT and PD-1 were highly variable among the analyzed samples. Highest levels of TIGIT and PD-1 were found in one sample of nodular lymphocytic-predominant HL (NLPHL). In conclusion, TIGIT expression is highly variable between patients with Hodgkin's lymphoma. Our results encourage further studies evaluating the role of TIGIT as a target for immunotherapies in Hodgkin's lymphoma.- Published
- 2018
- Full Text
- View/download PDF
28. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
- Author
-
Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Shadanpour N, Bannenberg C, Eichelberg C, Höflmayer D, Clauditz T, Wittmer C, Wilczak W, Sauter G, Fisch M, Rink M, and Eichenauer T
- Subjects
- Aged, Carcinoma, Papillary enzymology, Carcinoma, Papillary surgery, Carcinoma, Renal Cell enzymology, Carcinoma, Renal Cell surgery, Disease Progression, Female, Follow-Up Studies, Humans, Kidney Neoplasms enzymology, Kidney Neoplasms surgery, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local enzymology, Neoplasm Recurrence, Local surgery, Prognosis, Survival Rate, Antigens, Neoplasm metabolism, Biomarkers, Tumor metabolism, Carbonic Anhydrase IX metabolism, Carcinoma, Papillary secondary, Carcinoma, Renal Cell secondary, Cell Membrane metabolism, Kidney Neoplasms pathology, Neoplasm Recurrence, Local pathology
- Abstract
Objective: Antibodies against carbonic anhydrase IX (CAIX) are often part of immunohistochemical panels used to assist renal cell cancer (RCC) subtyping. This study was undertaken to determine, whether assessing CAIX expression levels could provide additional prognostic information., Methods and Materials: More than 1,800 RCCs were analyzed in a tissue microarray (TMA) format for CAIX expression. All tumors had been reviewed and newly classified according to the WHO 2016 classification., Results: Membranous CAIX expression revealed a "black and white" pattern that was strikingly dependent on the RCC subtype. In clear cell RCC, 89.2% of cancers showed strong positivity. The few clear cell RCC with lower CAIX expression levels were more likely to exhibit unfavorable tumor phenotype (p < 0.0001) and poor disease course (p = 0.0036). CAIX was completely absent in 99% of chromophobe RCC and in 100% of oncocytomas. In papillary RCC, 80.2% of cancers showed complete absence of CAIX staining. Papillary RCC with detectable CAIX expression had a less favorable tumor phenotype (p≤0.05) and worse disease outcome (p = 0.0176). These data are consistent with the concept, that "aberrant" CAIX staining - meaning absent or weak staining in a cancer expected to have a high level CAIX expression such as clear cell RCC or detectable CAIX expression in tumors that are typically CAIX negative such as papillary and chromophobe RCC - reflects biologic tumor dedifferentiation., Conclusion: Our data demonstrate that CAIX is a highly useful diagnostic biomarker for RCC providing both diagnostic and prognostic information., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
29. High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.
- Author
-
Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Jacobsen F, Huland H, Steurer S, Lebok P, Hinsch A, Wilczak W, Schlomm T, and Simon R
- Abstract
Approximately 50% of prostate cancer types harbor the transmembrane protease, serine 2: Erythroblast transformation-specific-related gene (ERG) fusion, resulting in oncogenic expression of the ERG transcription factor. ERG represents an attractive target for potential future anticancer therapy in advanced and metastatic prostate cancer. To better understand whether the analysis of the primary cancer is sufficient to estimate the ERG expression status of the lymph node metastases, the present study examined patterns of immunohistochemical ERG expression in a tissue microarray created from multiple primary and metastatic sites of 77 prostate cancer tissues. Among the identified tumor types, 80% were either entirely ERG-positive (38%) or ERG-negative (42%) across all (at least 9) analyzed different tumor sites. The results were heterogeneous in 20% of the tumor types and typically resulted from small ERG-negative areas within otherwise ERG-positive tumor types. Comparison of the ERG expression status in 51 primary cancer types with at least three interpretable lymph node metastases revealed an entirely identical ERG status in all tumor sites in 75% of the cases, including 16 ERG-positive and 22 ERG-negative cancer types. The remaining 13 cancer types exhibited ERG heterogeneity within the primary tumor, while all metastases had an identical (12 positive and 1 negative) ERG status. The results of the present study revealed a high degree of concordance of the ERG expression status between primary prostate cancer types and their lymph node metastases. Therefore, potential anti-ERG therapy may also be effective against lymph node metastases in the majority of cases of ERG-positive metastatic prostate cancer.
- Published
- 2018
- Full Text
- View/download PDF
30. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.
- Author
-
Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, and Schlomm T
- Subjects
- Aged, Biopsy, Humans, Immunohistochemistry, Kallikreins blood, Lymph Node Excision, Lymph Nodes chemistry, Lymph Nodes surgery, Lymphatic Metastasis, Lymphatic Vessels chemistry, Lymphatic Vessels surgery, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prostate-Specific Antigen blood, Prostatectomy, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Prostatic Neoplasms surgery, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Lymph Nodes pathology, Lymphatic Vessels pathology, Prostatic Neoplasms pathology
- Abstract
Background: Nodal metastasis (N1) is a strong prognostic parameter in prostate cancer; however, lymph node evaluation is always incomplete., Objective: To study the prognostic value of lymphatic invasion (L1) and whether it might complement or even replace lymph node analysis in clinical practice., Design, Setting, and Participants: Retrospective analysis of pathological and clinical data from 14 528 consecutive patients., Intervention: Radical prostatectomy., Outcome Measurements and Statistical Analysis: The impact of L1 and N1 on patient prognosis was measured with time to biochemical recurrence as the primary endpoint., Results and Limitations: Nodal metastases were found in 1602 (12%) of 13 070 patients with lymph node dissection. L1 was seen in 2027 of 14 528 patients (14%) for whom lymphatic vessels had been visualized by immunohistochemistry. N1 and L1 continuously increased with unfavorable Gleason grade, advanced pT stage, and preoperative prostate-specific antigen (PSA) values (p<0.0001 each). N1 was found in 4.3% of 12 501 L0 and in 41% of 2027 L1 carcinomas (p<0.0001). L1 was seen in 11% of 9868 N0 and in 61% of 1360 N1 carcinomas (p<0.0001). Both N1 and L1 were linked to PSA recurrence (p<0.0001 each). This was also true for 17 patients with isolated tumor cells (ie, <200 unequivocal cancer cells without invasive growth) and 193 metastases ≤1mm. Combined analysis of N and L status showed that L1 had no prognostic effect in N1 patients but L1 was strikingly linked to PSA recurrence in N0 patients. N0L1 patients showed a similar outcome as N1 patients., Conclusions: Analysis of lymphatic invasion provides comparable prognostic information than lymph node analysis. Even minimal involvement of the lymphatic system has pivotal prognostic impact in prostate cancer. Thus, a thorough search for lymphatic involvement helps to identify more patients with an increased risk for disease recurrence., Patient Summary: Already minimal amounts of tumor cells inside the lymph nodes or intraprostatic lymphatic vessels have a severe impact on patient prognosis., (Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
31. Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.
- Author
-
Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, and Wilczak W
- Abstract
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
- Published
- 2018
- Full Text
- View/download PDF
32. Immunohistochemically detected IDH1 R132H mutation is rare and mostly heterogeneous in prostate cancer.
- Author
-
Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz TS, Krech T, Tsourlakis MC, and Schroeder C
- Subjects
- Gene Deletion, Humans, In Situ Hybridization, Fluorescence, Isocitrate Dehydrogenase analysis, Male, Neoplasm Grading, Neoplasm Recurrence, Local, PTEN Phosphohydrolase genetics, Prostate-Specific Antigen analysis, Prostatic Neoplasms immunology, Prostatic Neoplasms pathology, Recombinant Fusion Proteins analysis, Serine Endopeptidases analysis, Transcriptional Regulator ERG analysis, Isocitrate Dehydrogenase genetics, Mutation, Prostatic Neoplasms genetics
- Abstract
Background: IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy., Methods: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1
R132H mutation., Results: IDH1 mutation-specific staining was found in 42 of 15,531 (0.3%) interpretable cancers. IDH1 mutation was associated with higher preoperative PSA and Gleason grade (p < 0.05, each) but was unrelated to PSA recurrence. A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer. Increased lethality of genetically instable, "aberration-rich" cancer cells in the presence of IDH1 mutations could possibly explain this observation. Heterogeneity analysis revealed a homogeneous mutation in only 1 of 16 IDH1-mutated cancers. This high degree of heterogeneity may profoundly limit therapeutic targeting of IDH1 mutations in prostate cancer., Conclusions: The data show that 0.3% of prostate cancers have an IDH1R132H mutation and that these are mostly heterogeneous. Once specific anti-IDH1 therapy becomes reality, only a very small group of prostate cancer patients may benefit from such a treatment.- Published
- 2018
- Full Text
- View/download PDF
33. Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
- Author
-
Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Krech T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzi E, Michl U, Budäus L, Tilki D, Thederan I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawahab AAA, Uhlig R, Huland H, Heinzer H, Graefen M, and Schlomm T
- Subjects
- Aged, Biopsy, Needle, Cohort Studies, Germany, Humans, Immunohistochemistry, Lymph Nodes pathology, Male, Middle Aged, Neoplasm Invasiveness pathology, Nomograms, Predictive Value of Tests, Prognosis, Prostatectomy methods, Retrospective Studies, Treatment Outcome, Neoplasm Grading, Neoplasm Recurrence, Local pathology, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery
- Abstract
Background: Presence of small (tertiary) Gleason 5 pattern is linked to a higher risk of biochemical recurrence in prostate cancer. It is unclear, however, how to integrate small Gleason 5 elements into clinically relevant Gleason grade groups., Objective: To analyze the prognostic impact of Gleason 5 patterns in prostate cancer and to develop a method for integrating tertiary Gleason 5 patterns into a quantitative Gleason grading system., Design, Setting, and Participants: Prostatectomy specimens from 13 261 consecutive patients and of 3295 matched preoperative biopsies were available. Percentages of Gleason 3, 4, and 5 had been recorded for each cancer. Outcome measurements and statistical analysis: RESULTS AND LIMITATIONS: Our data demonstrate that minimal Gleason 5 areas have strong prognostic impact in Gleason 7 carcinomas, while further expansion of the Gleason 5 pattern population has less impact. We thus defined an integrated quantitative Gleason score (IQ-Gleason) by adding a lump score of 10 to the percentage of unfavorable Gleason pattern (Gleason 4/5) if any Gleason 5 was present and by adding another 7.5 points in case of a Gleason 5 fraction >20%. There was a continuous increase of the risk of prostate-specific antigen recurrence with increasing IQ-Gleason. This was also true for subgroups with identical Cancer of the Prostate Risk Assessment Postsurgical scores (p<0.0001) or Gleason grade groups (p<0.0001)., Conclusions: The IQ-Gleason represents a simple and efficient approach for combining both quantitative Gleason grading and tertiary Gleason grades in one highly prognostic numerical variable., Patient Summary: Prostatectomy specimens (13 261) were analyzed to estimate the relevance of small Gleason 5 elements in prostate cancers. Even the smallest Gleason 5 areas markedly increased the risk of prostate-specific antigen recurrence after surgery. Larger fractions of Gleason 5 patterns had less further impact on prognosis. Based on this, a numerical Gleason score (integrated quantitative Gleason score) was defined by the percentages of Gleason 4 and 5 patterns, enabling a refined estimate of patient prognosis., (Copyright © 2017. Published by Elsevier B.V.)
- Published
- 2018
- Full Text
- View/download PDF
34. High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
- Author
-
Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, and Hinsch A
- Subjects
- Disease Progression, Estrogens genetics, Gene Expression Regulation, Neoplastic genetics, Humans, Male, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Biomarkers, Tumor genetics, Carcinogenesis genetics, Crk-Associated Substrate Protein genetics, Prostatic Neoplasms genetics
- Abstract
Background: Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression., Methods: To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion., Results: BCAR1 staining was barely detectable in normal prostate glands but seen in 77.6% of 9472 interpretable cancers, including strong expression in 38.5%, moderate in 23.2% and weak in 15.9% of cases. BCAR1 up regulation was associated with positive ERG status (p < 0.0001), high Gleason score (p < 0.0001), advanced pathological tumor stage (p = 0.0082), lower preoperative PSA level (p < 0.0001), increased cell proliferation (p < 0.0001), early PSA recurrence (p = 0.0008), and predicted prognosis independently from clinico-pathological parameters available at the time of the initial biopsy. However, subset analyses revealed that the prognostic impact of BCAR1 expression was limited to ERG-negative cancer. That BCAR1 up regulation was linked to almost all analyzed deletions (p < 0.0001 each for PTEN, 5q, 6q deletion) may suggest a functional link to genomic instability., Conclusion: The results of our study identify BCAR1 as a prognostic biomarker with potential clinical value for risk stratification of ERG-negative prostate cancer.
- Published
- 2018
- Full Text
- View/download PDF
35. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
- Author
-
Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, and Jacobsen F
- Subjects
- Adult, Aged, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local mortality, Proportional Hazards Models, Prostate-Specific Antigen blood, Prostatectomy, Prostatic Neoplasms mortality, Prostatic Neoplasms surgery, Transcriptional Regulator ERG genetics, Biomarkers, Tumor analysis, Hepatocyte Nuclear Factor 3-alpha biosynthesis, Neoplasm Recurrence, Local pathology, Prostatic Neoplasms pathology
- Abstract
FOXA1 (Fork-head box protein A1, HNF-3a) is a transcription factor involved in androgen signaling with relevance for lineage-specific gene expression of the prostate. The expression was analyzed by immunohistochemistry on a tissue microarray containing 11152 prostate cancer specimens. Results were compared with tumor phenotype, biochemical recurrence, androgen receptor expression, ETS-related gene (ERG) status and other recurrent genomic alterations. FOXA1 expression was detectable in 97.6% of 8227 interpretable cancers and considered strong in 28.5%, moderate in 46.2% and weak in 22.9% of cases. High FOXA1 expression was associated with TMPRSS2:ERG rearrangement and ERG expression (P < 0.0001). High FOXA1 expression was linked to high Gleason grade, advanced pathological tumor (pT) stage and early PSA recurrence in ERG negative cancers (P < 0.0001), while these associations were either weak or absent in ERG positive cancers. In ERG negative cancers, the prognostic role of FOXA1 expression was independent of Gleason grade, pathological tumor stage, lymph node stage, surgical margin status and preoperative PSA. Independent prognostic value became even more evident if the analysis was limited to preoperatively available features such as biopsy Gleason grade, preoperative PSA, cT stage and FOXA1 expression (P < 0.0001). Within ERG negative cancers, FOXA1 expression was also strongly associated with PTEN and 5q21 deletions (P < 0.0001). High expression of FOXA1 is an independent prognostic parameter in ERG negative prostate cancer. Thus, FOXA1 measurement might provide clinically useful information in prostate cancer., (© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
36. High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
- Author
-
Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz TS, Krech T, Tsourlakis MC, Minner S, Graefen M, Schlomm T, Wilczak W, and Jacobsen F
- Subjects
- Aged, Biomarkers, Tumor biosynthesis, Humans, Immunohistochemistry, Kallikreins metabolism, Male, Middle Aged, Neoplasm Recurrence, Local enzymology, Prognosis, Prostate-Specific Antigen metabolism, Tissue Array Analysis, Lactoylglutathione Lyase biosynthesis, Prostatic Neoplasms enzymology
- Abstract
Background: Glyoxalase 1 (GLO1) is an enzyme involved in removal of toxic byproducts accumulating during glycolysis from the cell. GLO1 is up regulated in many cancer types but its role in prostate cancer is largely unknown., Methods: Here, we employed GLO1 immunohistochemistry on a tissue microarray including 11 152 tumors and an attached clinical and molecular database., Results: Normal prostate epithelium was negative for GLO1, whereas 2059 (27.3%) of 7552 interpretable cancers showed cytoplasmic GLO1 staining, which was considered weak in 8.8%, moderate in 12.5%, and strong in 6.1% of tumors. Up regulation of GLO1 was significantly linked to high original Gleason grade, advanced pathological tumor stage and positive lymph node status (P < 0.0001 each). Comparison of GLO1 staining with several common genomic alterations of prostate cancers revealed a strong link between GLO1 up regulation and TMPRSS2:ERG fusion (P < 0.0001) and an ERG-independent association with PTEN deletion (P < 0.0001). GLO1 up regulation was strongly linked to early biochemical recurrence in univariate analysis (P < 0.0001) and predicted poor prognosis independent from most (except from nodal stage) established prognostic parameters in multivariate analysis (P ≤ 0.03)., Conclusions: GLO1 upregulation is linked to aggressive prostate cancers characterized by ERG fusion and PTEN deletion. The strong and independent prognostic value makes it a promising candidate for routine diagnostic applications either alone or in combination with other markers., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
37. Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.
- Author
-
Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS, Simon R, Sauter G, Izbicki JR, Clauditz TS, Luebke AM, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, and Melling N
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Cell Proliferation, Epithelium metabolism, Epithelium pathology, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Phenotype, Prognosis, Prostate-Specific Antigen metabolism, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Receptors, Androgen metabolism, Transcriptional Regulator ERG genetics, Transcriptional Regulator ERG metabolism, Biglycan metabolism, Gene Deletion, PTEN Phosphohydrolase genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism
- Abstract
Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P<.0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P<.0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P<.0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
38. Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.
- Author
-
Jacobsen F, Taskin B, Melling N, Sauer C, Wittmer C, Hube-Magg C, Kluth M, Simon R, Pehrke D, Beyer B, Steuber T, Thederan I, Sauter G, Schlomm T, Wilczak W, Möller K, Weidemann SA, and Burdak-Rothkamm S
- Subjects
- Aged, Cell Proliferation, Disease Progression, Disease-Free Survival, Genomic Instability, Humans, Kallikreins blood, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Proportional Hazards Models, Prostate-Specific Antigen blood, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Chromosome Aberrations, DNA-Binding Proteins metabolism, Endonucleases metabolism, Prostatic Neoplasms metabolism
- Abstract
Background: Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair Cross-Complementation Group 1) in prostate cancer progression., Methods: To better understand the impact of ERCC1 protein expression in human prostate cancer, a preexisting tissue microarray (TMA) containing more than 12,000 prostate cancer specimens was analyzed by immunohistochemistry and data were compared with tumor phenotype, PSA recurrence and several of the most common genomic alterations (TMPRSS2:ERG fusions: deletions of PTEN, 6q, 5q, 3p)., Results: ERCC1 staining was seen in 64.7% of 10,436 interpretable tissues and was considered weak in 37.1%, moderate in 22.6% and strong in 5% of tumors. High-level ERCC1 staining was linked to advanced pT stage, high Gleason grade, positive lymph nodes, high pre-operative serum PSA, and positive surgical margin status (p < 0.0001 each). High ERCC1 expression was strongly associated with an elevated risk of PSA recurrence (p < 0.0001). This was independent of established prognostic features. A subgroup analysis of cancers defined by comparable quantitative Gleason grades revealed that the prognostic impact was mostly driven by low-grade tumors with a Gleason 3 + 3 or 3 + 4 (Gleason 4: ≤5%). High ERCC1 expression was strongly associated with the presence of genomic alterations and expression levels increased with the number of deletions present in the tumor. These latter data suggest a functional relationship of ERCC1 expression with genomic instability., Conclusion: The results of our study demonstrate that expression of ERCC1 - a potential surrogate for genomic instability - is an independent prognostic marker in prostate cancer with particular importance in low-grade tumors.
- Published
- 2017
- Full Text
- View/download PDF
39. Epithelial crypts: A complex and enigmatic olfactory organ in African and South American lungfish (Lepidosireniformes, Dipnoi).
- Author
-
Wittmer C and Nowack C
- Subjects
- Africa, Animals, Epithelium ultrastructure, Nose anatomy & histology, Nose cytology, Nose ultrastructure, Olfactory Mucosa cytology, Olfactory Mucosa ultrastructure, Paraffin Embedding, South America, Epithelium anatomy & histology, Fishes anatomy & histology, Olfactory Mucosa anatomy & histology
- Abstract
African lungfish (Protopterus) seem unique among osteognathostomes in possessing a potential vomeronasal organ homolog in form of accessory epithelial crypts within their nasal cavity. Many details regarding structural and functional properties of these crypts are still unexplored. In this study, we reinvestigate the issue and also present the first data on epithelial crypts in the South American lungfish Lepidosiren paradoxa. The nasal cavities of L. paradoxa and Protopterus annectens were studied using histology, scanning electron microscopy, and alcian blue and PAS staining. In both species, the epithelial crypts consist of a pseudostratified sensory epithelium and a monolayer of elongated glandular cells, in accordance with previously published data on Protopterus. In addition, we found a new second and anatomically distinct type of mucous cell within the duct leading into the crypt. These glandular duct cells are PAS positive, whereas the elongated glandular cells are stainable with alcian blue, suggesting distinct functions of their respective secretions. Furthermore, the two lungfish species show differently structured crypt sensory epithelia and external crypt morphology, with conspicuous bilaterally symmetrical stripes of ciliated cells in L. paradoxa. Taken together, our data suggest that stimulus transport into the crypts involves both ciliary movement and odorant binding mucus., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
40. Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.
- Author
-
Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, and Wilczak W
- Abstract
Y-box binding protein 1 (YB-1) is an RNA and DNA binding factor with potential prognostic cancer. To evaluate the clinical impact of YB-1, a tissue microarray with 11,152 prostate cancers was analysed by immunohistochemistry. Cytoplasmic and nuclear staining was separately analysed. Cytoplasmic YB-1 was absent or weak in normal epithelium but seen in 86,3% of carcinomas. Cytoplasmic staining was weak, moderate, and strong in 29.6%, 43.7% and 13.0% of tumours and was accompanied by nuclear YB-1 staining in 32.1% of cases. Particularly nuclear staining was strongly linked to poor patient prognosis (p < 0.0001). YB-1 protein was more abundant in ERG positive (95.1%) than in ERG negative cancers (80.4%; p < 0.0001), but any prognostic impact of YB-1 staining was limited to the ERG-negative subset. Similarly, significant associations with pT stage and Gleason grade (p < 0.0001 each) were driven by the ERG negative subset. The significant association of YB-1 protein detection with deletions of PTEN, 5q21 and 6q15 fits well in the protein's role as an inhibitor of DNA damage dependent cell cycle arrest, a role that is likely to induce genomic instability. In summary, the data show, that the prognostic impact of YB-1 expression is limited to ERG negative prostate cancers.
- Published
- 2017
- Full Text
- View/download PDF
41. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.
- Author
-
Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl HU, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki JR, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, and Wilczak W
- Subjects
- Cell Proliferation, GTPase-Activating Proteins metabolism, Genetic Variation, Humans, Immunohistochemistry, Male, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Prognosis, Prostatic Neoplasms pathology, Survival Analysis, Biomarkers, Tumor, GTPase-Activating Proteins genetics, Gene Expression, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality
- Abstract
FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells. 67.5% of 9,633 interpretable cancers showed FAM13C expression: strong in 28.3%, moderate in 24.6% and weak in 14.6%. Strong FAM13C expression was linked to advanced pT stage, high Gleason grade, positive lymph node status, and early biochemical recurrence (p < 0.0001 each). FAM13C expression was associated with TMPRSS2:ERG fusions. It was present in 85% of ERG positive but in only 54% of ERG negative cancers (p < 0.0001), and in 91.1% of PTEN deleted but in only 69.2% of PTEN non-deleted cancers (p < 0.0001). The prognostic role of FAM13C expression was independent of classical and quantitative Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA. In conclusion, the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. Finding FAM13C also in non-neoplastic prostate tissues highlights the importance of properly selecting cancer-rich areas for RNA-based FAM13C expression analysis.
- Published
- 2017
- Full Text
- View/download PDF
42. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
- Author
-
Burdelski C, Fitzner M, Hube-Magg C, Kluth M, Heumann A, Simon R, Krech T, Clauditz T, Büscheck F, Steurer S, Wittmer C, Hinsch A, Luebke AM, Jacobsen F, Minner S, Tsourlakis MC, Beyer B, Steuber T, Thederan I, Sauter G, Izbicki J, Schlomm T, and Wilczak W
- Subjects
- ADAM Proteins genetics, Adult, Aged, Aged, 80 and over, Disease Progression, Disintegrins metabolism, Gene Expression, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Male, Membrane Proteins genetics, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality, Sequence Deletion, Serine Endopeptidases genetics, Serine Endopeptidases metabolism, Survival Analysis, Transcriptional Regulator ERG genetics, Transcriptional Regulator ERG metabolism, ADAM Proteins metabolism, Biomarkers, Tumor, Disintegrins genetics, Membrane Proteins metabolism, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology
- Abstract
The A Disintegrin and Metalloproteinase (ADAM) family of endopeptidases plays a role in many solid cancers and includes promising targets for anticancer therapies. Deregulation of ADAM15 has been linked to tumor aggressiveness and cell line studies suggest that ADAM15 overexpression may also be implicated in prostate cancer. To evaluate the impact of ADAM15 expression and its relationship with key genomic alterations, a tissue microarray containing 12,427 prostate cancers was analyzed by immunohistochemistry. ADAM15 expression was compared to phenotype, prognosis and molecular features including TMPRSS2:ERG fusion and frequent deletions involving PTEN, 3p, 5q and 6q. Normal prostate epithelium did not show ADAM15 staining. In prostate cancers, negative, weak, moderate, and strong ADAM15 staining was found in 87.7%, 3.7%, 5.6%, and 3.0% of 9826 interpretable tumors. Strong ADAM15 staining was linked to high Gleason grade, advanced pathological tumor stage, positive nodal stage and resection margin. ADAM15 overexpression was also associated with TMPRSS2:ERG fusions and PTEN deletions (P<.0001) but unrelated to deletions of 3p, 5q and 6q. In univariate analysis, high ADAM15 expression was strongly linked to PSA recurrence (P<.0001). However, in multivariate analyses this association was only maintained if the analysis was limited to preoperatively available parameters in ERG-negative cancers. The results of our study demonstrate that ADAM15 is strongly up regulated in a small but highly aggressive fraction of prostate cancers. In these tumors, ADAM15 may represent a suitable drug target. In a preoperative scenario, ADAM15 expression measurement may assist prognosis assessment, either alone or in combination with other markers., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
43. βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.
- Author
-
Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, and Jacobsen F
- Subjects
- Biomarkers, Tumor genetics, Biopsy, Cell Proliferation, DNA Copy Number Variations, Gene Dosage, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Neoplasm Grading, Neoplasm Staging, Phenotype, Tissue Array Analysis, Tumor Suppressor Protein p53 genetics, Up-Regulation, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology, Biomarkers, Tumor analysis, Genomic Instability, Tubulin analysis, Urinary Bladder Neoplasms chemistry
- Abstract
Development of genetic instability is a hallmark of tumor progression. Type III β-tubulin (TUBB3) is a component of microtubules involved in chromosome segregation. Its overexpression has been linked to adverse features of urinary bladder cancer. To investigate the role of TUBB3 for development of genetic instability, we compared TUBB3 expression with histopathological features and surrogate markers of genetic instability and tumor aggressiveness; copy number changes of HER2, TOP2A, CCND1, RAF1, and FGFR1; nuclear accumulation of p53, and cell proliferation in a tissue microarray (TMA) with more than 700 bladder cancers. TUBB3 expression was linked to high-grade and advanced-stage cancers (P<.0001), rapid cell proliferation (P<.0001), presence of multiple gene copy number alterations (P=.0008), and nuclear accumulation of p53 (P=.0008). Strong TUBB3 staining was found in 43% of urothelial cancers harboring copy number alterations as compared with 28% of genetically stable cancers, and in 50% of p53-positive cancers as compared with 30% of p53-negative tumors. The fraction of tumors with concomitant TUBB3 and p53 positivity increased with tumor stage and grade: 2% in pTaG1-2, 11% in pTaG3, 17% in pT1G2, 23% in pT1G3, and 32% in pT2-4 cancers (P<.0001). Importantly, strong TUBB3 overexpression was detectable in about 20% of low-grade, noninvasive cancers. In summary, our study demonstrates that TUBB3 overexpression is linked to an aggressive subtype of urinary bladder cancers, which is characterized by increased genetic instability, p53 alterations, and rapid cell proliferation. Detection of TUBB3 overexpression in genetically stable, low-grade, and noninvasive bladder cancers may be clinically useful to identify patients requiring particular close monitoring., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
44. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
- Author
-
Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Möller-Koop C, Steurer S, Sauter G, Jacobsen F, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis MC, Minner S, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, and Wilczak W
- Subjects
- Cell Proliferation, Gene Expression, Humans, Immunohistochemistry, Lymphatic Metastasis, Male, Margins of Excision, Neoplasm Grading, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms diagnosis, Prostatic Neoplasms surgery, Receptors, Androgen genetics, Receptors, Androgen metabolism, Recurrence, Sequence Deletion, Transcriptional Regulator ERG genetics, gamma-Glutamyl Hydrolase genetics, Biomarkers, Tumor, Prostatic Neoplasms metabolism, Prostatic Neoplasms mortality, Transcriptional Regulator ERG deficiency, gamma-Glutamyl Hydrolase metabolism
- Abstract
γ-glutamyl-hydrolase (GGH) is a ubiquitously-expressed enzyme that regulates intracellular folate metabolism for cell proliferation, DNA synthesis, and repair. Employing GGH immunohistochemistry on a tissue microarray with 12,427 prostate cancers, we found that GGH expression was negative to low in normal prostate epithelium, whereas 88.3% of our 10,562 interpretable cancers showed GGH expression. GGH staining was considered as low intensity in 49.6% and as high intensity in 38.6% of cancers. High GGH expression was linked to the TMPRSS2:ERG-fusion positive subset of cancers ( p < 0.0001), advanced pathological tumor stage, and high Gleason grade ( p < 0.0001 each). Further analysis revealed that these associations were merely driven by the subset of ERG-negative cancers, High GGH expression was weakly linked to early biochemical recurrence in ERG negative cancers ( p < 0.0001) and independent from established histo-pathological parameters. Moreover, GGH expression was linked to features of genetic instability, including presence of recurrent deletions at 3p, 5q, 6q, and 10q (PTEN, p ≤ 0.01 each), as well as to accelerated cell proliferation as measured by Ki67 immunohistochemistry ( p < 0.0001). In conclusion, the results of our study identify GGH as an ERG subtype specific molecular marker with modest prognostic relevance, which may have clinical relevance if analyzed in combination with other molecular markers.
- Published
- 2017
- Full Text
- View/download PDF
45. Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.
- Author
-
Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, and Schlomm T
- Published
- 2017
- Full Text
- View/download PDF
46. Deletion of 8p is an independent prognostic parameter in prostate cancer.
- Author
-
Kluth M, Amschler NN, Galal R, Möller-Koop C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Steurer S, Krech T, Büscheck F, Clauditz TS, Beyer B, Wilczak W, Graefen M, Huland H, Minner S, Schlomm T, Sauter G, and Simon R
- Subjects
- Aged, Biomarkers, Tumor blood, Chromosomes, Human, Pair 8, Disease Progression, Follow-Up Studies, Gene Deletion, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence methods, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostatic Neoplasms blood, Prostatic Neoplasms pathology, Tissue Array Analysis methods, Transcriptional Regulator ERG metabolism, Chromosome Deletion, Kallikreins blood, PTEN Phosphohydrolase genetics, Prostate-Specific Antigen blood, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality
- Abstract
Deletion of chromosome 8p is the second most frequent genomic alteration in prostate cancer. To better understand its clinical significance, 8p deletion was analyzed by fluorescence in-situ hybridization on a prostate cancer tissue microarray. 8p deletion was found in 2,581 of 7,017 cancers (36.8%), and was linked to unfavorable tumor phenotype. 8p deletion increased from 29.5% in 4,456 pT2 and 47.8% in 1,598 pT3a to 53.0% in 931 pT3b-pT4 cancers (P < 0,0001). Deletions of 8p were detected in 25.5% of 1,653 Gleason ≤ 3 + 3, 36.6% of 3,880 Gleason 3 + 4, 50.2% of 1,090 Gleason 4 + 3, and 51.1% of 354 Gleason ≥ 4 + 4 tumors (P < 0,0001). 8p deletions were strongly linked to biochemical recurrence (P < 0.0001) independently from established pre- and postoperative prognostic factors (P = 0.0100). However, analysis of morphologically defined subgroups revealed, that 8p deletion lacked prognostic significance in subgroups with very good (Gleason ≤ 3 + 3, 3 + 4 with ≤ 5% Gleason 4) or very poor prognosis (pT3b, Gleason ≥ 8, pN1). 8p deletions were markedly more frequent in cancers with (53.5%) than without PTEN deletions (36.4%; P < 0,0001) and were slightly more frequent in ERG-positive (40.9%) than in ERG-negative cancers (34.7%, P < 0.0001) due to the association with the ERG-associated PTEN deletion. Cancers with 8p/PTEN co-deletions had a strikingly worse prognosis than cancers with deletion of PTEN or 8p alone (P ≤ 0.0003). In summary, 8p deletion is an independent prognostic parameter in prostate cancer that may act synergistically with PTEN deletions. Even statistically independent prognostic biomarkers like 8p may have limited clinical impact in morphologically well defined high or low risk cancers.
- Published
- 2017
- Full Text
- View/download PDF
47. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
- Author
-
Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, Clauditz TS, Grupp K, Minner S, Tsourlakis MC, Möller-Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Izbicki JR, Huland H, Schlomm T, Steurer S, Krech T, and Lebok P
- Subjects
- Biomarkers, Tumor analysis, Case-Control Studies, DNA Mismatch Repair genetics, Follow-Up Studies, Humans, Immunoenzyme Techniques, Lymphatic Metastasis, Male, Neoplasm Grading, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local genetics, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Prognosis, Prostatectomy, Prostatic Neoplasms blood, Prostatic Neoplasms genetics, Up-Regulation, DNA-Binding Proteins genetics, Genomic Instability, Mismatch Repair Endonuclease PMS2 genetics, MutL Protein Homolog 1 genetics, Neoplasm Recurrence, Local pathology, Prostate-Specific Antigen blood, Prostatic Neoplasms pathology
- Abstract
DNA mismatch repair (MMR) is integral to the maintenance of genetic stability. We aimed to evaluate the clinical impact of MMR gene expression in prostate cancer. The MMR genes MSH6, MLH1 and PMS2 were analyzed by immunohistochemistry on a tissue microarray containing 11152 prostate cancer specimens. Results were compared with ETS-related gene status and deletions of PTEN, 3p13, 5q21 and 6q15. MSH6, MLH1 and PMS2 expression was detectable in 89.5%, 85.4% and 85.0% of cancers and was particularly strong in cancers with advanced pathological tumor stage (P < 0.0001 each), high Gleason grade (P < 0.0001 each), nodal metastasis (P ≤ 0.0083) and early biochemical recurrence (P < 0.0001). High levels of MMR gene expression paralleled features of genetic instability, such as the number of genomic deletions per cancer; strong expression of all three MMR genes was found in 24%, 29%, 30%, 33% and 42% of cancers with no, one, two, three or four to five deletions (P < 0.0001). The prognostic value of the analyzed MMR genes was largely driven by the subset of cancers lacking ERG fusion (P < 0.0001), while the prognostic impact of MMR gene overexpression was only marginal in ERG-positive cancers. Multivariate analyses suggested an independent prognostic relevance of MMR genes in ERG-negative prostate cancers when compared with prognostic parameters available at the time of initial biopsy. In conclusion, MMR overexpression is common in prostate cancer and is linked to poor outcome as well as features indicating genetic instability. ERG fusion should be analyzed along with MMR gene expression in potential clinical tests., (© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
48. Deletion of 18q is a strong and independent prognostic feature in prostate cancer.
- Author
-
Kluth M, Graunke M, Möller-Koop C, Hube-Magg C, Minner S, Michl U, Graefen M, Huland H, Pompe R, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Büscheck F, Clauditz T, Wilczak W, Sauter G, Schlomm T, and Simon R
- Subjects
- Adult, Aged, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, Prognosis, Prostate-Specific Antigen blood, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Transcriptional Regulator ERG genetics, Chromosome Deletion, Chromosomes, Human, Pair 18, Prostatic Neoplasms genetics
- Abstract
Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successfully analyzed cancers (7.5%). 18q deletion was linked to unfavorable tumor phenotype. An 18q deletion was seen in 6.4% of 4,360 pT2, 8.0% of 1,559 pT3a and 11.8% of 930 pT3b-pT4 cancers (P < 0.0001). Deletions of 18q were detected in 6.9% of 1,636 Gleason ≤ 3 + 3, 6.8% of 3,804 Gleason 3 + 4, 10.1% of 1,058 Gleason 4+3, and 9.9% of 344 Gleason ≥ 4 + 4 tumors (P = 0.0013). Deletions of 18q were slightly more frequent in ERG-fusion negative (8.2%) than in ERG-fusion positive cancers (6.4%, P = 0.0063). 18q deletions were also linked to biochemical recurrence (BCR, P < 0.0001). This was independent from established pre- and postoperative prognostic factors (P ≤ 0.0004). In summary, the results of our study identify 18q deletion as an independent prognostic parameter in prostate cancer. As it is easy to measure, 18q deletion may be a suitable component for multiparametric molecular prostate cancer prognosis tests.
- Published
- 2016
- Full Text
- View/download PDF
49. Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.
- Author
-
Tsourlakis MC, Stender A, Quaas A, Kluth M, Wittmer C, Haese A, Graefen M, Steurer S, Simon R, Korbel J, Weischenfeldt J, Huland H, Sauter G, Schlomm T, and Minner S
- Subjects
- Adult, Aged, Humans, Male, Middle Aged, Prostatectomy, Prostatic Neoplasms metabolism, Transcriptional Regulator ERG metabolism, Tumor Burden, Genetic Heterogeneity, Oncogene Proteins, Fusion metabolism, Prostatic Neoplasms surgery
- Abstract
Background: TMPRSS2:ERG fusions are frequent in prostate cancer, and occur predominantly in young patients. Several studies had proposed intratumoral heterogeneity of these fusions. This study was designed to determine frequency and extent of ERG fusion heterogeneity in early-onset prostate cancer (EO-PCA, <50 years) and in elderly patients., Methods: The prostates from 63 EO-PCA and 62 elderly prostate cancer patients were thoroughly reviewed for presence of cancer foci. All 1592 tumor-containing sections were analyzed by immunohistochemistry for ERG expression., Results: The prostates included in this study contained one tumor focus in 44, two tumor foci in 21, three tumor foci in 32, four tumor foci in 15, and five or more tumor foci in 13 patients. Among 59 cancer foci with ≤3 mm, 19 (32.2 %) were homogeneously ERG positive, 39 66.1 %) were homogeneously ERG negative, and one case (1.7 %) showed a heterogeneous ERG status. The fraction of homogeneously ERG positive cancer foci remained largely constant (14-37 %) with increasing tumor focus diameter but the fraction of heterogeneous ERG findings continuously increased with tumor size and reached 39 % in cancer foci larger than 22 mm. On a patient level, ERG expression was markedly more frequent in EO-PCA than in elderly patients: 13 % of EO-PCA were homogeneously and 62 % were heterogeneously ERG positive. In elderly patients, 3 % of cancers were homogeneously and 57 % were heterogeneously ERG positive (p = 0.0721)., Conclusion: These data show that about 20-30 % of prostate cancer foci have early ERG fusions. ERG fusions further occur in about 50 % of initially ERG negative cancer foci during cancer progression. The vast majority of cancers are heterogeneous for TMPRSS2:ERG fusions on a patient level, challenging the concept of classifying prostate cancer patients into "fusion type" and "non-fusion type" prostate cancer.
- Published
- 2016
- Full Text
- View/download PDF
50. The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer.
- Author
-
Lennartz M, Minner S, Brasch S, Wittmann H, Paterna L, Angermeier K, Öztürk E, Shihada R, Ruge M, Kluth M, Koop C, Wilczak W, Krech T, Lebok P, Wittmer C, Heinzer H, Steuber T, Adam M, Huland H, Graefen M, Haese A, Simon R, Sauter G, and Schlomm T
- Subjects
- Chromosomes, Human, Pair 6 genetics, Disease-Free Survival, Humans, Kallikreins blood, Male, Multivariate Analysis, Neoplasm Grading, Ploidies, Prognosis, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Sequence Deletion, PTEN Phosphohydrolase genetics, Prostatic Neoplasms genetics
- Abstract
Purpose: Aberrant DNA content has been discussed as a potential prognostic feature in prostate cancer., Experimental Design: We analyzed the clinical significance of DNA ploidy in combination with prognostic relevant deletions of PTEN and 6q15 in 3,845 prostate cancers., Result: The DNA status was diploid in 67.8%, tetraploid in 25.6%, and aneuploid in 6.8% of tumors, and deletions of PTEN and 6q15 occurred in 17.8% and 20.3% of tumors. Abnormal DNA content and deletions were linked to high Gleason score, advanced tumor stage, and positive nodal stage (P < 0.0001 each). The risk of PSA recurrence increased from diploid to tetraploid and from tetraploid to aneuploid DNA status (P < 0.0001 each). However, 40% of patients with Gleason score ≥4+4 and 55% of patients with PSA recurrence had diploid cancers. This fraction decreased to 21% (Gleason ≥4+4) and 29% (PSA recurrence) if PTEN and/or 6q deletion data were added to ploidy data to identify cancers with an aberrant DNA status. The significance of combining both deletions and ploidy was further demonstrated in a combined recurrence analysis. Presence of deletions increased the risk of PSA recurrence in diploid (P < 0.0001), tetraploid (P < 0.0001), and aneuploid cancers (P = 0.0049), and the combination of ploidy data and deletions provided clinically relevant information beyond the CAPRA-S nomogram. Multivariate modeling including preoperatively and postoperatively available parameters identified the "combined DNA status" as a strong independent predictor of poor patient outcome., Conclusions: The combinatorial DNA content analysis involving general (ploidy) and specific events (deletions) has the potential for clinical utility in prostate cancer. Clin Cancer Res; 22(11); 2802-11. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.